Beta Bionics (NASDAQ:BBNX) Trading Up 13.7% – Here’s What Happened

Beta Bionics, Inc. (NASDAQ:BBNX) shares were up 13.7% on Friday . The company traded as high as $15.84 and last traded at $16.0450. 649,324 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,156,924 shares. The stock had previously closed at $14.11.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BBNX shares. Leerink Partners dropped their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Bank of America reduced their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Beta Bionics in a research note on Friday, July 17th. The Goldman Sachs Group increased their target price on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus reduced their price target on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics Stock Performance

The firm has a market capitalization of $723.17 million, a PE ratio of -9.74 and a beta of 3.13. The company’s 50 day simple moving average is $15.16 and its 200-day simple moving average is $13.08.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The firm had revenue of $32.01 million during the quarter. On average, equities research analysts forecast that Beta Bionics, Inc. will post -2.1 earnings per share for the current fiscal year.

Insider Transactions at Beta Bionics

In other news, insider Mike Mensinger sold 4,378 shares of Beta Bionics stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $55,206.58. Following the completion of the sale, the insider owned 184,415 shares in the company, valued at approximately $2,325,473.15. This trade represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Jon Russell sold 4,222 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $53,239.42. Following the transaction, the insider directly owned 173,849 shares of the company’s stock, valued at $2,192,235.89. The trade was a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 40,351 shares of company stock worth $553,961. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC boosted its holdings in Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after acquiring an additional 240,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Beta Bionics during the fourth quarter valued at $40,437,000. UBS Group AG grew its holdings in shares of Beta Bionics by 96.6% during the fourth quarter. UBS Group AG now owns 251,438 shares of the company’s stock valued at $7,661,000 after buying an additional 123,533 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its position in shares of Beta Bionics by 4,236.8% during the first quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock valued at $4,868,000 after buying an additional 474,651 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Beta Bionics during the fourth quarter valued at approximately $1,566,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.